Index
Checking point of information
at the time of initial public offering.
AI Analysis
■AI Analysis
AI statistically analyzes IPO information to identify trends.
The closer the number is to 5, the higher the rate of increase in the initial price relative to the offering price.
| popularity | scale-criteria | offering-criteria | exchange-criteria | market-condition | Business-criteria |
| 3 | 3 | 5 | 5 | 3 | 1 |
*This is an analysis of trends and does not guarantee any results.
This is not a solicitation to buy or sell stocks, nor is it investment advice.
*Please check the disclaimer for details.
■AI Analysis Chart
A group of stocks listed in the past
with similar IPO condition trends
| Name | Rate of change
(Inicial Price) |
|
| +77.6% |
|
| +151.6% |
|
| +44.0% |
|
| +26.5% |
|
| +92.8% |
|
| +164.0% |
CompanyOverview
- Company Name：Kringle PharmaInc
- Business：HGF（肝細胞増殖因子）タンパク質を用いた難治性疾患の治療薬の研究開発.
- The industry sector is Pharmaceutical.
- Scheduled to be listed on MOTHERS.
- The company size is that assumed market capitalization is
approx. 36 Million JPY (excluded public offering), approx. 42 Million JPY (included public offering).
- The lead manager is 野村.
https://www.kringle-pharma.com/
Initial Public Offering Memo
■ Market Cap | Offering rate | Dilution rate | lock-up information
- The company size is assumed market capitalization is
approx. 36 Million JPY (excluded new issues), approx. 42 Million JPY (included new issues).
- The total amount of new issues is 5.8 Million JPY.
- The total amount of public offering is 0.9 Million JPY.
- The dilution ratio from the new issues is 16%.
- Rate of offering is aprrox. 2%.
- The number of outstanding shares is 3,647,700 shares (excluded new issues),
4,227,700 shares (included new issues).
- The number of diluted shares for stock acquisition rights is 485,000 shares.
- Date of 90-day lockup release (initially scheduled) is March 27, 2021.
- Date of 180-day lockup release (initially scheduled) is June 25, 2021.
■ Book building schedule | Payment schedule
- Book building Period *1：December 10, 2020(Thu.) - December 16, 2020(wed.)
- Priced date *2 ：December 17, 2020(Thu.)
- Payment Period *3 ：December 18, 2020(Fri.) - December 23, 2020(wed.)
- Listing Date ：December 28, 2020(Mon.)
*1:(Period for applying lottery to obtain the right to purchase)
*2:(The date when the purchase price is determined)
*3:(Period for expressing your intent to purchase and payment,if you are selected in the lottery)
■ Detail of new issue or public offering
- Unit of application：100 shares (Minimum deposit amount is 100,000 JPY.)
- Assumed issue price：950 JPY
- Tentatively price range：950 JPY - 1000 JPY
- Public offering price：1000 JPY
- The initial price on listed：1480 JPY(＋48.0％)
- Newly Issued Shares：580,000 shares (Domestic：580,000 shares ＋ Overseas：0 shares)
- Public offering shares：87,000 shares (Domestic：87,000 shares ＋ Overseas：0 shares)
- Number of domestic unit：6,670 Unit
- The lead manager is 野村證券.
- The another securities companies are ＳＢＩ証券/ＳＭＢＣ日興証券/楽天証券/三菱ＵＦＪモルガン・スタンレー証券/いちよし証券/東洋証券/エース証券/岡三証券.
| 野村 |
ＳＢＩ |
ＳＭＢＣ日興 |
楽天 |
三菱ＵＦＪモルガン・スタンレー |
いちよし |
東洋 |
エース |
岡三 |
| Lead |
Sub |
Sub |
Sub |
Sub |
Sub |
Sub |
Sub |
Sub |
■ New issue or public offering - condition history
|
Update
date |
Assumed issue
price
(JPY) |
Tentatively
price range
(JPY) |
Public offering
price
(JPY) |
| Initial | 2020-11-24 | 950 JPY | | |
| Application period | 2020-12-09 | | 950 - 1000 JPY | |
| Priced | 2020-12-17 | | | 1000 JPY |
|
Update
date |
New issues
total shares |
New issues
(Overseas) |
PO&OA
total shares |
PO
(Domestic) |
PO
(Overseas) |
OA
(Domestic) |
OA
(Overseas) |
| Initial | 2020-11-24 | 580,000 | 0 | 87,000 | 0 | 0 | 87,000 | 0 |
| Application period | 2020-12-09 | 580,000 | 0 | 87,000 | 0 | 0 | 87,000 | 0 |
| Priced | 2020-12-17 | 580,000 | 0 | 87,000 | 0 | 0 | 87,000 | 0 |
※：( ) indicates the breakdown.
e.g. In the case of a PO(overseas), there are domestic and overseas allotments of the public offering, of which the overseas allotment is indicated.
PO : Public offering OA : Over allotment
